Compare Star Health Insu with Similar Stocks
Dashboard
Strong Long Term Fundamental Strength with a 19.27% CAGR growth in Operating Profits
Poor long term growth as Net Sales has grown by an annual rate of -50.00%
Flat results in Dec 25
With ROE of 6, it has a Very Expensive valuation with a 3.8 Price to Book Value
High Institutional Holdings at 35.03%
Stock DNA
Insurance
INR 27,599 Cr (Small Cap)
63.00
22
0.00%
0.06
5.99%
3.71
Total Returns (Price + Dividend) 
Star Health Insu for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Star Health & Allied Insurance Company Ltd is Rated Hold
Star Health & Allied Insurance Company Ltd is rated 'Hold' by MarketsMOJO. This rating was last updated on 30 January 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 13 February 2026, providing investors with the latest perspective on the company’s performance and valuation.
Read full news article
Star Health & Allied Insurance Upgraded to Hold on Financial and Technical Improvements
Star Health & Allied Insurance Company Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a stabilisation in its financial performance and a shift towards a more positive technical outlook. Despite challenges in profitability and valuation concerns, the company’s recent quarterly results and market behaviour have prompted analysts to revise their stance, signalling cautious optimism for investors.
Read full news article
Star Health & Allied Insurance Sees Technical Momentum Shift Amid Mixed Indicator Signals
Star Health & Allied Insurance Company Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend on the daily charts. Despite mixed signals from key technical indicators such as MACD, RSI, and moving averages, the stock’s recent price action and relative strength against the Sensex suggest cautious optimism among investors.
Read full news article Announcements 
Announcement under Regulation 30 (LODR)-Change in Directorate
11-Feb-2026 | Source : BSEStar Health and Allied Insurance Company Limited has informed the exchange regarding appointment of Mr. Himanshu Walia and Mr. Amitabh Jain as Whole-time Directors and Key Managerial Personnel with effect from February 11 2026.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
06-Feb-2026 | Source : BSEStar Health and Allied Insurance Company Limited has informed the exchange regarding schedule of meet with Group Analysts/Investors dated February 11 2026.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
06-Feb-2026 | Source : BSEStar Health and Allied Insurance Company Limited has informed the exchange regarding schedule of meet with Analysts/Investors dated February 11 2026.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 20 Schemes (12.95%)
Held by 174 FIIs (14.07%)
Safecrop Investments India Llp (40.19%)
Icici Prudential Life Insurance Company Limited (4.79%)
4.38%
Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is 4.16% vs 3.62% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is 133.55% vs -79.09% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 11.00% vs 15.60% in Sep 2024
Growth in half year ended Sep 2025 is -26.22% vs 4.13% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 11.30% vs 15.52% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -30.95% vs -8.16% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 14.56% vs 14.89% in Mar 2024
YoY Growth in year ended Mar 2025 is -23.57% vs 36.60% in Mar 2024






